T 1101

Drug Profile

T 1101

Alternative Names: T1101; Tosylate

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taivex
  • Developer Development Center for Biotechnology; Taivex Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 21 Nov 2017 Taivex Therapeutics Corporation plans a phase I trial for Solid tumours in Taiwan in December 2017 (NCT03349073),
  • 01 Jul 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Taiwan (PO) (NCT03195764)
  • 08 Aug 2016 Preclinical development is ongoing in Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top